凯时联合阿托伐他汀治疗颈动脉粥样硬化的临床疗效及对C反应蛋白的影响  

Clinical effects of alprostadil combined with atorvastatin in patients with carotid atherosclerosis and effects on CRP

作　　者：杜顺波[1] 赵咏梅[2] 

机构地区：[1]绵阳市第三人民医院高新分院,四川绵阳621006 [2]江油市中国燃气涡轮研究院职工医院,四川江油621703

出　　处：《四川医学》2011年第11期1754-1756,共3页Sichuan Medical Journal

摘　　要：目的探讨凯时联合阿托伐他汀治疗颈动脉粥样硬化(CAS)的临床疗效及其对C-反应蛋白(CRP)的影响。方法 90例CAS患者随机分为治疗组和对照组。对照组给予阿托伐他汀治疗,治疗组采用凯时联合阿托伐他汀治疗,治疗6个月后评价临床疗效。测定血清CRP和血脂水平。结果治疗组临床疗效总有效率为91.1%,显著高于对照组(66.7%),相比较有统计学意义(P<0.05);治疗后,两组血清CRP、TC、TG、LDL水平与治疗前比较明显降低(P<0.05),且治疗组与对照组比较有统计学意义(P<0.05);两组HDL水平与治疗前比较明显上升(P<0.05),且治疗组与对照组比较有统计学意义(P<0.05)。结论凯时和阿托伐他汀治疗CAS临床疗效好,具有降低CRP水平,改善脂质代谢的作用。Objective To investigate the clinical effects of alprostadil combined with atorvastatin in patients with carotid atherosclerosis（CAS） and effects on CRP.Methods 90 cases with CAS patients were divided randomly into the treatment group and control group.The control group＇s patients were given the atorvastatin calcium therapy,and the treatment group＇s patients were given the treatment of alprostadil combined with atorvastatin.The clinical efficacy was observed after treatment for 6 months.The serum CRP and lipid levels were detected.Results The clinical total effective rate of the treatment group was 91.1%,it was significantly higher than that of the control group（66.7%）,compared with the control group the difference was significant（P0.05）;After treatment,the serum CRP,TC,TG and LDL levels of the two groups decreased significantly,compared with prior-treatment the difference was significant（P0.05）,and the treatment group compared with control group the difference was significant（P0.05）;The HDL levels of the two groups increased significantly,compared with prior-treatment the difference was significant（P0.05）,and the treatment group compared with control group the difference was significant（P0.05）.Conclusion The alprostadil combined with atorvastatin in patients with CAS has better clinical efficacy,can reduce CRP levels and improved lipid metabolism.

关 键 词：颈动脉粥样硬化 凯时 阿托伐他汀 

分 类 号：R543.4[医药卫生—心血管疾病]